Skip to main content

Peer Review reports

From: Comparison of the efficacy and safety between rivaroxaban and dabigatran in the treatment of acute portal vein thrombosis in cirrhosis

Original Submission
16 Mar 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
7 May 2023 Reviewed Reviewer Report
17 Jun 2023 Reviewed Reviewer Report
1 Jul 2023 Author responded Author comments - Yikuan Chen
Resubmission - Version 3
1 Jul 2023 Submitted Manuscript version 3
10 Jul 2023 Author responded Author comments - Yikuan Chen
Resubmission - Version 4
10 Jul 2023 Submitted Manuscript version 4
10 Jul 2023 Author responded Author comments - Yikuan Chen
Resubmission - Version 5
10 Jul 2023 Submitted Manuscript version 5
23 Jul 2023 Reviewed Reviewer Report
24 Jul 2023 Reviewed Reviewer Report
12 Aug 2023 Reviewed Reviewer Report
19 Aug 2023 Author responded Author comments - Yikuan Chen
Resubmission - Version 6
19 Aug 2023 Submitted Manuscript version 6
24 Aug 2023 Reviewed Reviewer Report
26 Aug 2023 Reviewed Reviewer Report
29 Aug 2023 Author responded Author comments - Yikuan Chen
Resubmission - Version 7
29 Aug 2023 Submitted Manuscript version 7
Publishing
15 Sep 2023 Editorially accepted
25 Sep 2023 Article published 10.1186/s12876-023-02960-8

You can find further information about peer review here.

Back to article page